Compare Twist Bioscience Corp (TWST) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wynn Resorts, Limited — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.26B), while Wynn Resorts, Limited trades at $90.11 (market cap $9.29B). The key difference: Twist Bioscience Corp and Wynn Resorts, Limited are close in size by market cap, and Wynn Resorts, Limited pays a 1.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WYNN | |
|---|---|---|
Market Cap | $8.26B | $9.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $153.10 | $133.34 |
52-Week Low | $24.16 | $90.23 |
Enterprise Value | $8.18B | $19.53B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, with a bearish technical signal and mixed earnings. Q2 2026 EPS beat estimates at $1.24, but Q4 2025 and Q1 2026 missed. Revenue reached $7.14B in 2025, with net income margin at 6.06%. Recent news highlights Macau strength offset by U.S. margin pressure and rising capital expenditures for new projects.
Outlook: Analyst consensus is bullish with a $132.44 price target, but risks include high debt ($10.5B long-term), profit margin compression, and significant capital spending. The stock offers growth potential from Macau recovery and new developments, yet faces headwinds from operational costs and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
